{
    "id": "correct_subsidiary_00047_1",
    "rank": 71,
    "data": {
        "url": "https://investors.bio-techne.com/board-of-directors",
        "read_more_link": "",
        "language": "en",
        "title": "Board of Directors :: Bio",
        "top_image": "https://resources.bio-techne.com/images/Social/2019-bio-techne-logo.png",
        "meta_img": "https://resources.bio-techne.com/images/Social/2019-bio-techne-logo.png",
        "images": [
            "https://d1io3yog0oux5.cloudfront.net/_2b8e087fabbc5d849e5f0bdb5afb699e/biotechne/db/320/2148/photo_resized.jpg",
            "https://d1io3yog0oux5.cloudfront.net/_2b8e087fabbc5d849e5f0bdb5afb699e/biotechne/db/320/2150/photo_resized.jpg",
            "https://d1io3yog0oux5.cloudfront.net/_2b8e087fabbc5d849e5f0bdb5afb699e/biotechne/db/320/2516/photo_resized.jpg",
            "https://d1io3yog0oux5.cloudfront.net/_2b8e087fabbc5d849e5f0bdb5afb699e/biotechne/db/320/2154/photo_resized.jpg",
            "https://d1io3yog0oux5.cloudfront.net/_2b8e087fabbc5d849e5f0bdb5afb699e/biotechne/db/320/2155/photo_resized.jpg",
            "https://d1io3yog0oux5.cloudfront.net/_2b8e087fabbc5d849e5f0bdb5afb699e/biotechne/db/320/2219/photo_resized.jpg",
            "https://d1io3yog0oux5.cloudfront.net/_2b8e087fabbc5d849e5f0bdb5afb699e/biotechne/db/320/2220/photo_resized.jpg",
            "https://d1io3yog0oux5.cloudfront.net/_2b8e087fabbc5d849e5f0bdb5afb699e/biotechne/db/320/2290/photo_resized.jpg",
            "https://d1io3yog0oux5.cloudfront.net/_2b8e087fabbc5d849e5f0bdb5afb699e/biotechne/db/320/2348/photo_resized.jpg",
            "https://d1io3yog0oux5.cloudfront.net/_2b8e087fabbc5d849e5f0bdb5afb699e/biotechne/db/320/2532/photo_resized.jpg",
            "https://d1io3yog0oux5.cloudfront.net/_2b8e087fabbc5d849e5f0bdb5afb699e/biotechne/files/site-files/20200806/sites/default/files/2020-07/logo.png",
            "https://d1io3yog0oux5.cloudfront.net/_2b8e087fabbc5d849e5f0bdb5afb699e/biotechne/files/site-files/20200806/themes/custom/bio_techne_global/images/icon_social_facebook.svg",
            "https://d1io3yog0oux5.cloudfront.net/_2b8e087fabbc5d849e5f0bdb5afb699e/biotechne/files/site-files/20200806/themes/custom/bio_techne_global/images/icon_social_twitter.svg",
            "https://d1io3yog0oux5.cloudfront.net/_2b8e087fabbc5d849e5f0bdb5afb699e/biotechne/files/site-files/20200806/themes/custom/bio_techne_global/images/icon_social_linkedin.svg",
            "https://d1io3yog0oux5.cloudfront.net/_2b8e087fabbc5d849e5f0bdb5afb699e/biotechne/files/site-files/20200806/themes/custom/bio_techne_global/images/icon_social_youtube.svg",
            "https://d1io3yog0oux5.cloudfront.net/_2b8e087fabbc5d849e5f0bdb5afb699e/biotechne/files/site-files/20200806/themes/custom/bio_techne_global/images/icon_social_instagram.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "https://d1io3yog0oux5.cloudfront.net/_2b8e087fabbc5d849e5f0bdb5afb699e/biotechne/files/site-files/20200806/themes/custom/bio_techne_one/favicon.ico",
        "meta_site_name": "Bio-Techne Corporation",
        "canonical_link": "https://investors.bio-techne.com/board-of-directors",
        "text": "Mr. Baumgartner has served on the Company's Board since 2003 and as Chairman since 2012. Until July of 2019, Mr. Baumgartner served as Executive Chairman, Director of the Center for Diagnostic Imaging, Inc., an operator of diagnostic imaging centers. Until August, 2015, Mr. Baumgartner also served as Chief Executive Officer of that company. Prior to 2001, he held numerous executive positions, including as Chief Executive Officer and Director of American Coating International, President and Chief Executive Officer of First Solar and President of the Apogee Glass Group. He began his professional career at KPMG LLC, an international accounting firm. Mr. Baumgartner currently serves on the board of Carestream Health, Inc.\n\nJohn L. Higgins has served on the Company's Board since 2009. Mr. Higgins has been President and Chief Executive Officer of Ligand Pharmaceuticals, Inc. since January 2007 and has been a member of Ligand's Board of Directors since March 2007. From 1997 until joining Ligand, Mr. Higgins was with Connetics Corporation, a specialty pharmaceutical company, as its Chief Financial Officer, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics from January 2002 until its acquisition by Stiefel Laboratories, Inc. in December 2006. Mr. Higgins was previously a member of the executive management team and a director at BioCryst Pharmaceuticals, Inc., a biopharmaceutical company. Mr. Higgins also serves as Chairman of CoMentis, Inc., a biopharmaceutical company, and has served as a director of numerous public and private companies.\n\nKim Kelderman has been President, Chief Executive Officer, and member of the Board of the Company since February 1, 2024. Kim joined Bio-Techne on April 30, 2018, as President, Diagnostics and Genomics and served as Chief Operating Officer of the Company from November 1, 2023 to January 31, 2024. Prior to Bio-Techne, Mr. Kelderman was employed at Thermo Fisher Scientific where he led three different businesses of increasing scale and complexity. For the last three years, Mr. Kelderman managed the Platforms and Content of the Genetic Sciences Division, where he was responsible for the Instrumentation, Software, Consumables and Assays businesses, and brands such as Applied Biosystems and legacy Affymetrix. Before joining Thermo Fisher, Kim served as Senior Segment Leader at Becton Dickinson, managing the global Blood Tubes \"Vacutainer\" business.\n\nRoeland Nusse, Ph.D., has served on the Company's Board since May 2010. Dr. Nusse has served as Chairman of the Department of Developmental Biology at Stanford University since 2007. Dr. Nusse has been a professor or associate professor in the Department of Developmental Biology at Stanford University and an investigator at the Howard Hughes Medical Institute since 1990. He has also been the chair of the Department of Developmental Biology at Stanford since 2007. Dr. Nusse was previously at the Netherlands Cancer Institute (Amsterdam, The Netherlands) as a staff scientist and ultimately head of the Department of Molecular Biology. Dr. Nusse was elected to the United States National Academy of Sciences in April 2010. Dr. Nusse was previously named a member of the European Molecular Biology Organization in 1988, a member of the Royal Dutch Academy of Sciences in 1997 and a member of the American Academy of Arts and Sciences in 2001.\n\nRandolph C. Steer, M.D., Ph.D., has served on the Company's Board since 1990. Dr. Steer is currently an independent biotechnology consultant. He served as President and Chief Operating Officer of Capstone Therapeutics Corp. from April 2006 to October 2011. Dr. Steer was elected to the Mayo Clinic Board of Trustees in November 2011. In the past five years, Dr. Steer also served as a director of Vital Therapies, Inc. From 1989 to 2006 Dr. Steer was a consultant to the pharmaceutical and biotechnology industries, where he advised companies in business development, medical marketing and regulatory and clinical affairs. His prior experience includes service as Associate Director of Medical Affairs at Marion Laboratories and as Medical Director at Ciba Consumer Pharmaceuticals.\n\nDr. Joseph Keegan currently serves as a director and advisor for Interpace Biosciences (Nasdaq: IDXG) as well as a number of privately held life science companies, including executive director at Carterra, Inc., and director at Nanomedical Diagnostics. From 2007 until its sale to Pall Corporation in 2012, Dr. Keegan served as President and Chief Executive Officer of ForteBio, Inc. Dr. Keegan joined ForteBio from Molecular Devices Corporation, where he served as President and Chief Executive Officer from 1998 to 2007. Prior to Molecular Devices, Dr. Keegan held leadership positions at Becton Dickinson, Leica, Inc. and GE Medical Systems. He has also served on numerous public and private company boards of life science tools companies. Dr. Keegan holds a Ph.D. in Physical Chemistry from Stanford University. Among other attributes, skills and qualifications, the Board believes Dr. Keegan is qualified to serve as a Director of the Company because of his deep knowledge of our industry and customers, as well as his extensive executive management experience and prior service on other private and public company boards.\n\nDr. Alpna Seth formerly served as President and Chief Executive Officer of Nura Bio, a venture capital funded biotech company focused on novel therapeutics for serious neurodegenerative diseases spanning central, peripheral and ocular nervous systems. The company is headquartered in South San Francisco. Previously, Dr. Seth was Chief Operating Officer of Vir Biotechnology, Inc. Prior to joining Vir in July 2017, Dr. Seth was Senior Vice President and Global head of the Biosimilars business for Biogen, Inc. headquartered in Zug, Switzerland since 2014. For the period from 1998 through 2014, Dr. Seth held a range of executive roles at Biogen in business development, drug development and marketing programs. She holds a Ph.D. in Biochemistry and Molecular Biology from University of Massachusetts Medical School. Dr. Seth brings a breadth of experience in drug discovery, marketing, international operations and business development. Among other attributes, skills and qualifications, the Board believes Dr. Seth’s extensive background in the pharmaceutical industry and her deep knowledge of critical areas of science provide a valuable strategic perspective for our business generally and for a key customer group for the Company.\n\nRupert Vessey, MA, BM BCh, FRCP, DPhil is currently Executive Partner and Chief Scientist at Flagship Pioneering. Previously, Dr. Vessey was the President of Global Research and Early Development at Bristol-Myers Squibb, a position he also held at Celgene prior to its acquisition by Bristol-Myers Squibb. Before joining Celgene, Dr. Vessey held various research and development senior management positions at Merck. Prior to his ten years at Merck, Dr. Vessey worked in drug discovery, experimental medicine, and early clinical development at GlaxoSmithKline. Dr. Vessey holds an MA in physiological sciences and a BM BCh in clinical medicine from Oxford University where he completed his DPhil at the Institute for Molecular Medicine, Oxford along with additional clinical training at various hospitals in the UK. He is a member of the Royal College of Physicians of London UK.\n\nBushman is the former Executive Vice President of International Operations for 3M. She previously served in various executive positions at 3M, including as Senior Vice President of Business Transformation and Information Technology; Executive Vice President of Safety, Security and Protection Services; Executive Vice President of Safety and Graphics; Division Vice President of the Occupational Health and Environmental Safety Division; and Chief Information Officer. Bushman joined 3M in 1983.\n\nBushman currently serves as a director of Adient plc, an automotive seating company and Phillips 66, an energy manufacturing and logistics company. She previously served as a director of Johnson Controls from 2012 through 2016.\n\nDr. Klimovsky has served on the Company’s Board of Directors since 2024. Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company specialized in the creation and development of antibody therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held various senior global clinical and research positions at Novartis Oncology, a division of Novartis AG, including SVP & Global Head, Oncology Clinical Development. Dr. Klimovsky also served as Regional Medical Director, Latin America for Merck & Co. and held several research and development roles of increasing responsibility at Bristol-Myers Squibb Company. Dr. Klimovsky received her M.D. from the Universidad de Buenos Aires."
    }
}